Xuriden

Description

Xuriden (uridine triacetate)

Background
Xuriden is used to treat hereditary orotic aciduria, an extremely rare genetic disorder where the body cannot make uridine due to a deficient enzyme. Uridine is a critical component of ribonucleic acid (RNA), which plays a vital role in countless cell functions. The disease generally manifests itself as blood abnormalities, urinary tract obstruction (due to formation of orotic acid crystals in the urinary tract), failure to thrive, and developmental delays. Xuriden works by replacing uridine so that RNA can continue with its necessary function (1).

Regulatory Status
FDA approved indication: Xuriden is a pyrimidine analog for uridine replacement indicated for the treatment of hereditary orotic aciduria (1).

Related policies

Policy
This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Xuriden may be considered medically necessary for patients with hereditary orotic aciduria.
Xuriden may be considered investigational in patients for all other indications.

**Prior-Approval Requirements**

**Diagnosis**

Patient must have the following:

Hereditary orotic aciduria

---

**Prior – Approval Renewal Requirements**

Same as above

---

**Policy Guidelines**

**Pre - PA Allowance**

None

**Prior - Approval Limits**

**Duration** 2 years

---

**Prior – Approval Renewal Limits**

Same as above

---

**Rationale**

**Summary**

Xuriden is a pyrimidine analog indicated for hereditary orotic aciduria. Hereditary orotic aciduria is a rare genetic disorder. The safety and effectiveness of Xuriden have been established in pediatric patients with hereditary orotic aciduria (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Xuriden while maintaining optimal therapeutic outcomes.

**References**

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 6, 2019 and is effective on January 1, 2020.